ASTERDM - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 2.9

ASTERDM is showing signs of momentum recovery but remains technically indecisive and fundamentally expensive. The surge in quarterly profit makes it an interesting watch, yet its poor volume and weak RSI hold it back from being a high-conviction swing trade at this stage.

📈 Technical Breakdown

RSI (49.9): Neutral, teetering at the edge of strength—needs to push past 52 for bullish momentum.

MACD (0.58): Slightly positive but not convincing yet—no crossover signal.

Volume Slump: Current volume is less than half the weekly average, indicating low trader participation.

50 DMA > 200 DMA: Bullish crossover already happened, but price is hovering near 50 DMA—suggests consolidation rather than breakout.

📊 Fundamentals Review

High P/E (76.9) vs Industry P/E (69.2): Overvalued, implying low margin for error.

PEG (-8.78): Negative value makes it hard to assess growth-adjusted valuation.

ROE (10.5%) & ROCE (10.7%): Low returns relative to sector leaders.

Debt-to-Equity (0.59): Moderate gearing—adds risk in adverse conditions.

EPS (108 ₹) seems strong, but may be inflated by Qtr Profit spike.

🔍 Institutional Flow

FII Holding Change (-2.02%): Foreign investors exiting could be a red flag.

DII Hold (+0.70%): Marginal confidence from domestic players.

🟢 Entry Plan

Entry Range: ₹582–₹588

Conditions to watch

RSI crosses 53

Price closes above ₹600 with volume >9L

MACD strengthens above 1.2

🧭 Exit Strategy (If Already Holding)

Short-Term Target: ₹610–₹620 (nearest resistance)

Mid-Term Target: ₹640–₹650 (if momentum strengthens)

Stretch Target: ₹665+ only if volume spikes and RSI exceeds 60

Stop Loss: ₹570 (just below 50 DMA)

💡 Final Take

ASTERDM is intriguing for swing enthusiasts who don’t mind a bit of technical ambiguity paired with explosive earnings growth. It’s in the “watch with caution” zone—improved momentum and volume are essential to unlock real swing potential.

Want to dig into how it stacks up against Apollo Hospitals or Fortis Healthcare next? Could be a good cross-check for healthcare sector rotation. Let’s slice into it. 🏥📊

Edit in a page